Other articles

To Get Wet-AMD Gene Therapy To Finish Line 4DMT Reduces Workforce By 25%

Biogen To Move Salanersen Forward As Alternative SMA Therapy To ZOLGENSMA Non Responders

Nektar’s Rezpeg Hopes Revived After Latest Atopic Dermatitis Treatment Data

Merck Gets RSV Vaccine Approval From FDA Pitting It Against Beyfortus

Otsuka Sibeprenlimab Achieves Impressive Proteinuria Reduction In IgAN Patients

Despite Phase 2 Trial Failure In ALSP For Vigil, Sanofi Acquisition Still On Right Track

MoonLake Sought Out For By Merck For $3 Billion To Add Sonelokimab To Arsenal, FT Reports

PD-1/VEGF Market Heats Up With Bristol-Myers Squibb And BioNTech $11.1B Tie-Up

Kymera Achieves Positive STAT6 Protein Degrader Results In Healthy Volunteer Study

Summit Reports Mixed Ivonescimab Data But Path Forward Might Remain

Keros Pulls Final Plug On PAH Drug Cibotercept

iTeos Doubles Down On Strategic Alternatives After TIGIT Failures

Rocket Stock Takes A Dive On Patient Death For Gene Therapy RP-A501

Amazing Survival Feat In Solid Tumors Achieved With Merus Petosemtamab

Sanofi Buys Vigil In $470 Million Deal For Alzheimer’s TREM2 Drug

UroGen Draws A Split Adcom Panel Vote For Bladder Cancer Drug UGN-102

Prime Medicine Not Keen On PM359 Advancement Despite Initial Data

CRISPR Scores Win For CTX310 Targeting Cholesterol Patients

Vertex Pauses Study Of VX-522 For Patients With Cystic Fibrosis

Biomea Takes Workforce Reduction Play Of 35% For Realignment Plans

Scroll to Top